Skip to main content
Menu

Endocrinology - Weekly Reports

List of weekly reports on Endocrinology

Weekly Endocrinology Research Analysis

This week in endocrinology was dominated by mechanistic discoveries that reveal new immunometabolic axes, and by clinical trials that may change practice. A translational mechanistic study identified thromboxane signalling as an immunometabolic driver of skeletal muscle glucose uptake with preserved efficacy in obesity. A randomized trial of pelacarsen demonstrated large apheresis-sparing effects and profound Lp(a) lowering in secondary prevention, and a phase 3 study showed once-weekly somapaci

Weekly Endocrinology Research Analysis

This week’s endocrinology literature emphasizes mechanistic advances in human pancreatic differentiation, genomics linking lipid-handling genes to progressive MASLD and hepatocellular carcinoma, and the prognostic importance of dual-organ ectopic fat (liver and pancreas) for cardiometabolic multimorbidity and cardiac remodeling. Together the top studies span single-cell multi-omics with a tractable T1D-like human model and pharmacologic rescuers, large multi-cohort genetics that reframe MASLD ri

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlights several mechanistic discoveries that nominate druggable targets (intestinal aPKC/GLUT1 for glucose excretion; FAK/PYK2 as leptin‑signaling nodes enabling leptin sensitization) and a translational liver biology axis (MTARC1–phospholipid remodeling) that protects against metabolic fatty liver. Together these papers shift attention toward tissue‑specific signaling and organ crosstalk as therapeutic entry points and support near-term translational effo

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlights mechanistic redefinition of a marketed lipid drug (bempedoic acid) as a direct PPARα activator, robust pediatric evidence that inclisiran safely and durably lowers LDL-C in adolescents with HeFH, and a head-to-head phase 3 trial showing sepiapterin’s superiority over sapropterin in PKU. Large MASLD studies also refined non-invasive fibrosis testing with subgroup-specific thresholds, supporting precision diagnostics. Collectively, these papers advan

Weekly Endocrinology Research Analysis

This week’s endocrinology literature spans mechanistic discoveries that reshape developmental and immune biology and large clinical trials that change practice. A Science paper identifies an ERV-driven chimeric RNA network (MLT2A1) essential for human zygotic genome activation, suggesting embryo-competence biomarkers. A Nature Metabolism study defines an IL-21–centered T cell–NK cell crosstalk in type 1 diabetes remission, revealing a new therapeutic axis. A large BMJ randomized trial shows natu

Weekly Endocrinology Research Analysis

This week highlighted mechanistic and translational advances that nominate tissue- and time-specific drivers of metabolic disease and actionable targets. A preclinical human-integrated study identifies adipocyte-specific sclerostin loop3–LRP4 signaling as a precision target to improve lipid and glucose metabolism. Endothelial FUNDC1 was shown to link vascular mitochondrial signaling to systemic insulin resistance via a SIRT3/GATA2/ET-1 axis. Human isotope-based diurnal phenotyping revealed night

Weekly Endocrinology Research Analysis

This week’s endocrinology literature emphasized mechanistic insights that open translational paths: an endothelial ER‑stress checkpoint (IRE1α→THBS1) was shown to enable adaptive islet vascularization and insulin secretion under metabolic stress; a mitochondrial carrier (SLC25A45) governing carnitine biosynthesis and fuel switching was identified; and a liver GPCR (GPR110) coupled to ERα explains a female-biased susceptibility to MASH. Collectively these studies prioritize vascular, mitochondria

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlights three high-impact pieces: a large multicenter RCT shows PGT-A does not improve live birth rates in ICSI for severe male infertility while reducing miscarriage; a mechanistic Diabetologia study identifies ENPP2 and the LPA–LPAR2–Akt/mTOR axis as a promising beta‑cell compensatory target; and a prespecified exploratory analysis of the SELECT trial finds weekly semaglutide 2.4 mg reduces total hospitalizations and inpatient days in people with obesity

Weekly Endocrinology Research Analysis

This week highlighted high-impact work spanning metabolic programming, reproductive genomics, and diabetes therapeutics. A mechanistic preclinical study identified a breast‑milk EV miRNA → HIF1AN/AMPK/αKG axis that imprints durable thermogenic memory in brown fat, suggesting actionable prevention targets. A large double‑blinded non‑selection IVF study showed that reporting putative PGT‑A mosaicism does not improve live‑birth prediction and should not guide routine embryo selection. A large CVOT

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlights several paradigm-shifting mechanistic discoveries and clinically actionable diagnostics. A Nature Communications paper defines a CYP51A1-mediated bypass enabling androgen synthesis independent of CYP17A1, with clear implications for resistance in prostate cancer. PNAS and Cell Metabolism papers reveal novel mechanistic axes — LGALSL driving central sensitization in diabetic neuropathic pain and muscle‑derived mitochondrial vesicles impairing cognit

Weekly Endocrinology Research Analysis

This week’s endocrinology literature crossed mechanistic insights, computational resources, and translational signals. A Nature Communications paper reveals a CYP51A1-mediated bypass that enables androgen biosynthesis independent of CYP17A1, redefining steroidogenesis and resistance mechanisms in prostate cancer. Large single-cell and translational studies (JCI insight, JCI) map immune and receptor-level regulators in autoimmune diabetes and endometrial estrogen responses, suggesting new biomark

Weekly Endocrinology Research Analysis

This week’s endocrinology literature spotlights therapeutic innovation and mechanistic breakthroughs. A large phase-3 trial demonstrated robust, durable weight loss with the first late‑phase oral small‑molecule GLP‑1 receptor agonist in people with type 2 diabetes, potentially overcoming barriers to injectable incretins. Mechanistic studies revealed a stress-driven insulin neoepitope sustaining autoreactive memory T cells in type 1 diabetes and, separately, that fructose can rapidly induce MASLD

Weekly Endocrinology Research Analysis

This week featured high-impact translational work spanning precision nutrition, functional genomics for endocrine oncology, and a druggable mechanistic target in diabetic kidney disease. A randomized multi-omics trial showed baseline gut microbiota controls resistant-starch efficacy in MASLD and identified a probiotic strain that rescues nonresponders. A functional cellular assay reclassified SDHB variants with immediate clinical genetics impact for hereditary pheochromocytoma/paraganglioma. NUA

Weekly Endocrinology Research Analysis

This week produced high-impact advances across therapeutics, prevention trials, and mechanistic endocrinology. A pair of NEJM randomized trials showed that an APOC3 antisense (olezarsen) powerfully lowers triglycerides and reduces pancreatitis events, while genotype-stratified prevention signals emerged from a large POInT RCT for oral insulin. Mechanistic preclinical work (Cell Metabolism) revealed adipocyte-derived extracellular vesicles carrying leptin-sensitizing miRNAs as a reversible driver

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlights mechanistic advances with clear translational potential and a phase‑3 randomized therapeutic win. High-resolution structural biology identified an adipocyte regulator (adipogenin) that stabilizes seipin to drive lipid droplet biogenesis, offering a new axis for lipid‑storage disorders. A peptide (spexin) was shown to bind ATP1A1 and restore β‑cell function in preclinical models, advancing beta‑cell–targeted therapeutic strategies. Finally, a phase‑

Weekly Endocrinology Research Analysis

This week’s endocrinology literature emphasized precision phenotyping, translational therapeutic targets, and scalable prevention. A large multi-cohort clustering study defined four reproducible PCOS subtypes with distinct reproductive and metabolic outcomes, enabling subtype-based risk stratification. Translational mechanistic work identified FAM20C as a druggable adipocyte kinase linking obesity to inflammation and insulin resistance. Pragmatic clinical evidence showed an AI-powered Diabetes P

Weekly Endocrinology Research Analysis

This week in endocrinology featured high-impact clinical trials and translational discoveries that could change practice: a Lancet prespecified analysis showing semaglutide’s cardioprotective effects extend beyond simple weight loss; a JAMA multicenter RCT demonstrating closed-loop insulin systems substantially improve pregnancy time-in-range in type 1 diabetes; and a JCEM phase 3 trial introducing an effective once-daily oral SSTR2 agonist (paltusotine) for acromegaly. Complementary mechanistic

Weekly Endocrinology Research Analysis

This week in endocrinology was dominated by high-impact translational and functional-genomic work: a comprehensive INSR deep-mutational map enables rapid functional classification of ~14,000 receptor variants and points to antibody-amenable defects for precision therapy. Human adrenocortical organoids demonstrate functional steroidogenesis, in vivo rescue of adrenal insufficiency, and disease modeling for PRKACA-driven Cushing’s, advancing regenerative approaches. Large human genetics work shows

Weekly Endocrinology Research Analysis

This week’s endocrinology literature emphasized mechanistic discoveries that directly inform translational strategies: (1) a human islet transcriptomics study mapped β‑cell recovery signatures that may guide disease‑modifying therapies for type 2 diabetes; (2) mechanistic work identified TRAF6 as a mitophagy node essential for β‑cell adaptation to metabolic stress, suggesting mitophagy-directed targets; and (3) an exosomeborne metabolic sensor (CtBP2) extended healthspan in mice and emerged as a

Weekly Endocrinology Research Analysis

This week’s endocrinology literature emphasizes shifts from mechanism to clinic: (1) a large trial analysis shows prediabetes remission — even without weight loss — reduces progression to type 2 diabetes, highlighting glycemic targets and adipose redistribution as key mediators; (2) mechanistic JCI work implicates SAM-dependent H3K27me3 as a mediator of SGLT2 inhibitor renal protection, opening biomarker and target opportunities; and (3) a randomized trial demonstrates a Bayesian decision-suppor

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlights durable progress on three fronts: adaptive immunotherapy dose-optimization that preserves beta-cell function in recent-onset type 1 diabetes (Lancet); discovery of a hepatocyte caspase‑8–YY1–meteorin axis driving MASH fibrosis, opening new anti-fibrotic targets (Nature Metabolism); and identification of a lysosomal LRRC8 anion channel program linking organelle pH to mTOR signaling and systemic insulin sensitivity (Science Advances). Together these

Weekly Endocrinology Research Analysis

This week saw major advances across obesity therapeutics, diabetes technology, and endocrine pathophysiology. Large phase‑3 trials and a landmark NEJM study showed robust efficacy for novel GLP‑1–based and oral GLP‑1 therapies (including dose escalation and an oral small molecule), while translational work revealed new targets (α‑cell FATP2) and adrenal signaling mechanisms (FGFR2). Diagnostic and precision‑medicine innovations — from CGM‑based postpartum diabetes detection to phenotype‑driven m

Weekly Endocrinology Research Analysis

This week highlighted mechanistic discovery in monogenic neonatal diabetes (TMEM167A implicating ER-to-Golgi trafficking), large-scale genetic subtyping that reframes obesity by separating adiposity from cardiometabolic risk, and a high-impact phase 3 trial showing substantial weight loss with once-daily oral semaglutide 25 mg. Across the week, multiomics, single-cell transcriptomics, and optimized diagnostic assays (LC‑MS/MS) advanced risk prediction and screening, while real-world and trial da

Weekly Endocrinology Research Analysis

This week in endocrinology highlighted mechanistic discoveries that reframe neuroendocrine control of metabolism, late-stage clinical advances in endocrine-targeted therapies, and deep molecular catalogs that reshape autoimmune diabetes research. A Nature study mapped an amygdala–liver circuit controlling stress hyperglycaemia, a phase‑3 NEJM trial introduced baxdrostat as an effective aldosterone synthase inhibitor for resistant hypertension, and a proteogenomic Diabetes paper discovered hundre

Weekly Endocrinology Research Analysis

This week’s endocrinology literature emphasized translational mechanistic discoveries and high-impact therapeutic/diagnostic advances. Top findings include a microbiota-derived peptide (corisin) as a targetable driver of diabetic kidney fibrosis, branched-chain amino acid–PKM2 pathways linking amino acid dysmetabolism to podocyte failure in DKD, and human GCGR loss-of-function variants mechanistically tied to early hepatic steatosis. Complementary clinical and imaging advances—inclisiran improvi

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlights mechanistic genomics, impactful surgical outcomes, and novel molecular tools. A functional genomics study links DENND1A regulatory variation to androgen excess in PCOS, providing a causal bridge from GWAS to phenotype. A large multicentre randomized trial in The Lancet shows SADI-S yields superior 2‑year weight loss versus Roux‑en‑Y with comparable safety, influencing bariatric practice. Advanced molecular probes (fluorescent dual GLP1R/GIPR agonis

Weekly Endocrinology Research Analysis

This week’s endocrinology literature combined high‑impact mechanistic discoveries, large evidence syntheses, and pragmatic clinical trials. A mechanistic Nature Communications paper nominates G3BP1 as a druggable autophagy node in MASLD/MASH. A comprehensive living network meta-analysis (BMJ) provides risk‑stratified, practice‑facing comparisons of modern type 2 diabetes therapies. A randomized mHealth‑supported resistance training trial (Diabetes Care) shows safe insulin dose reductions in yout

Weekly Endocrinology Research Analysis

This week featured high-impact translational advances across diabetes cell therapy, microbiome enzymology, and wound-healing biology. A pluripotent stem cell-derived islet reconstruction achieved full endocrine subtype composition and in vivo hypoglycemia protection, an AI pipeline mapped hundreds of thousands of microbial bile-acid enzymes and discovered a novel bile-acid skeleton, and mechanistic work revealed galectin-3/integrin α5β1 phase separation as a druggable pathway to restore diabetic

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlights an emerging immunometabolic therapeutic axis (ACLY inhibition) that reshapes the tumor microenvironment in MASH-driven liver cancer; a mechanistic discovery (NCOA7-driven granulophagy) that redefines ovarian aging and provides mRNA/pharmacologic rescue strategies; and microbiome-derived peptides (RORDEPs) with systemic incretin‑modulating and metabolic benefits in preclinical models. Together these studies push translational boundaries from epigene

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlights mechanistic discoveries that nominate druggable targets and near-term translational candidates, alongside a promising new osteoporosis biologic. A preclinical/translational triad (PGK1 in DKD, LONP1 in β-cell mitochondrial proteostasis) provides both biomarker candidates and small-molecule or pathway-based intervention strategies. A phase II randomized anti‑RANKL antibody (narlumosbart) demonstrates meaningful BMD gains, advancing the antiresorptiv

Weekly Endocrinology Research Analysis

This week’s endocrinology research clustered around precision phenotyping/AI, new mechanistic insights into islet signaling, and a translational therapeutic candidate targeting FSH. A large deep-phenotyping cohort (Human Phenotype Project) introduced a multi-modal AI foundation model that improves metabolic risk prediction. Mechanistic work revealed GLP1R pre-internalization at alpha–beta contacts as an organizer of islet paracrine signaling, while a humanized FSH-blocking antibody provided IND-

Weekly Endocrinology Research Analysis

This week’s endocrinology literature emphasized mechanistic immunometabolism, targetable immune pathways for therapy-related autoimmune diabetes, and metabolic resilience mechanisms relevant to obesity therapeutics. High-impact translational work identified T follicular helper cell–driven checkpoint-inhibitor diabetes that is preventable with JAK inhibition, and adipose-resident immune circuits (IFNα–IFNAR–CD8+ T cells) that sustain obesity-linked inflammation. Complementary metabolic studies re

Weekly Endocrinology Research Analysis

This week’s endocrinology literature emphasized human-to-mechanism translation and clinical risk stratification. A JCI paper identified a common glucocorticoid receptor variant (rs6190) that drives hypercholesterolemia and atherosclerosis via hepatic PCSK9/BHLHE40 with sex-specific effects, pointing to actionable lipid targets. A Molecular Metabolism study established complete PAX4 loss as a novel cause of transient neonatal diabetes and mapped PAX4-regulated islet networks using CRISPR‑iPSC and

Weekly Endocrinology Research Analysis

This week was dominated by high-impact trials advancing obesity and diabetes pharmacotherapy and by diagnostic biomarker and precision-genomics work that could change clinical pathways. Notable therapeutics include a monthly GLP-1/GIP-pathway multiagonist (maridebart cafraglutide) with double-digit, durable weight loss and large combination incretin trials (cagrilintide‑semaglutide) showing major weight and glycemic benefits, alongside once‑weekly basal insulin programs (efsitora) simplifying in

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlights rapid translation of novel metabolic therapeutics, mechanistic advances in β‑cell and neuroendocrine biology, and large comparative/registry studies that shape clinical practice. First‑in‑class agents (SANA) and tissue‑targeted approaches (adipocyte FGF21) advance new anti‑obesity mechanisms, while BRD4–ATF5 epigenetic control of β‑cell identity suggests a target to prevent dedifferentiation. Large systematic reviews and real‑world cohorts (MEN1 me

Weekly Endocrinology Research Analysis

This week’s endocrinology literature emphasized mechanistic discoveries that reveal new therapeutic axes for metabolic disease and improved risk stratification tools. Preclinical work identified METRNL as a beta‑cell fate guardian and obesity‑driven islet endothelial VEGF‑A desensitization as a durable driver of impaired insulin delivery, pointing to novel targets to preserve insulin secretion and microvascular function. Large‑scale human metabolomics produced an interpretable nomogram that subs

Weekly Endocrinology Research Analysis

This week’s endocrinology literature was dominated by translational advances that could change screening, diagnosis, and treatment pathways. A validated miRNA-based dynamic risk score (Nature Medicine) promises earlier, generalizable stratification for type 1 diabetes and prediction of therapeutic response. Large randomized and pragmatic trials (Lancet Diabetes & Endocrinology; NEJM) support simplified once‑weekly fixed‑ratio insulin–GLP‑1RA regimens and additive renoprotective benefit from fine

Weekly Endocrinology Research Analysis

This week’s endocrinology literature was dominated by translational discoveries that bridge mechanism to clinical impact: (1) a Cell paper deorphanized an MRGPRE‑mediated microbiome–bile‑acid axis (Trp‑CA) that improves glucose tolerance and nominates a new GPCR drug target; (2) a New England Journal of Medicine phase‑3 trial showed once‑weekly mazdutide (GLP‑1/glucagon dual agonist) produces double‑digit mean weight loss with broad cardiometabolic benefit; and (3) a multi‑center transcriptomic

Weekly Endocrinology Research Analysis

This week’s endocrinology literature emphasized translational mechanisms that link molecular biology to clinical practice, scalable diagnostic innovations, and pragmatic therapeutic targets. Key advances include an epigenetic mechanism (H3K27ac loss) impairing endometrial receptivity and fertility, mechanistic and early randomized human data supporting L‑carnitine to correct impaired fatty acid oxidation in diabetic kidney disease, and prospective validation of plasma multimetabolite signatures

Weekly Endocrinology Research Analysis

This week’s endocrinology literature delivered high-impact, practice-informing results: a head-to-head randomized trial showed tirzepatide produced greater and clinically meaningful weight and waist reductions than semaglutide over 72 weeks. Large-scale human genetics integrated with MR and functional follow-up identified DGKD, SLC34A1, and CYP24A1 as actionable pathways for kidney stone disease, suggesting genotype-guided prevention and druggable targets. A multicenter randomized trial (CHIRACI

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlights translational advances linking diet, microbiome, and circadian biology to metabolic regulation, a novel gut–liver–pancreas neuroimmune axis driving adaptive β-cell expansion during obesity, and a high-quality phase 3 trial showing a single‑pill CETP inhibitor–ezetimibe combination markedly reduces LDL-C. Collectively the work emphasizes timing- and mechanism-informed interventions (dietary and pharmacologic) and reinforces precision approaches (gen

Weekly Endocrinology Research Analysis

This week showed rapid advances across endocrine diagnostics, therapeutics, and mechanistic biology. A phase‑3 trial established semaglutide 2.4 mg weekly as histologically effective for MASH with F2–F3 fibrosis. Noninvasive AI using retinal images (DeepDKD) demonstrated robust detection and triage capabilities for diabetic kidney disease across multi‑ethnic cohorts. Mechanistic and translational studies also reframed lipid and microbiome drivers in metabolic liver disease, while safety and prec

Weekly Endocrinology Research Analysis

This week’s endocrinology literature prioritized mechanistic discoveries in adipose and hepatic metabolism, reaffirmed the protective and regulatory roles of ketogenesis in fatty liver disease, and advanced spatial and single‑cell approaches that redefine metabolic zonation. Several translational signals emerged: targetable age-enriched adipose progenitors (LIFR/CP-A), spatially plastic hepatic gluconeogenesis with β-catenin and glutamine flux implications, and ketogenesis as a hepatoprotective

Weekly Endocrinology Research Analysis

This week in endocrinology emphasized mechanistic circuits linking metabolism to behavior and organ physiology, spatial and kinase-level reprogramming in hepatic insulin resistance, and an unexpected hematology–metabolism coupling affecting glycemia. Key clinical advances included refined diagnostic workflows (LC‑MS/MS for AVS, consensus MASLD/MASH algorithms) and large-scale population genomics that prompt reconsideration of genetic screening thresholds. Together the papers push translational t

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlights translational advances that span mechanistic discoveries to pragmatic clinical evidence. Top discoveries include a newly identified molecular brake on UCP1-independent Ca2+-cycling thermogenesis (drug-targetable for obesity), macrophage-derived sEV miRNA drivers of liver fibrosis in MASH, and human microbiome–metabolome signatures that mediate impaired glucose control and respond to lifestyle change. Real-world and trial-emulating studies further r

Weekly Endocrinology Research Analysis

This week delivered cross-cutting advances: a mechanistic Science paper defines an intestinal FXR → GLP-1 gut–joint axis with therapeutic implications for osteoarthritis; a methodological Nature Communications paper (LEOPARD) provides a robust AI approach to complete missing views in longitudinal multi-omics enabling better temporal biomarker discovery; and a JCI physiology study shows meal timing drives ghrelin-dependent growth hormone pulsatility that preserves skeletal growth. Collectively th

Weekly Endocrinology Research Analysis

This week highlighted advances that span immediate clinical practice and foundational discovery. Large randomized-trial meta-analytic evidence reinforced class-level cardiorenal and mortality benefits of long-acting GLP-1 receptor agonists (including oral semaglutide), supporting broader therapeutic adoption. Mechanistic human and preclinical studies exposed new pathways amenable to intervention — from a first-in-class BMAL1 small molecule for clock-directed immunometabolism to GPR119/TFEB and e

Weekly Endocrinology Research Analysis

This week’s endocrinology literature features high-impact advances across therapeutics, translational immunometabolism, and cross-ancestry metabolomics. A multicenter randomized trial shows automated insulin delivery (AID) meaningfully improves glycemic control and time-in-range in insulin-treated type 2 diabetes. Translational Hepatology work identifies neutrophil proteases (NE, PR3) under miR‑223/STAT3 control as druggable drivers of MASH fibrosis, while cross-ancestry metabolomics GWAS with M

Weekly Endocrinology Research Analysis

This week in endocrinology featured high-impact translational and mechanistic studies. A genomic–phenotypic–functional integration produced a high-performance pathogenicity–severity classifier for MCT8 variants, directly improving diagnosis and trial stratification for a treatable rare endocrine transporter disorder. Mechanistic work uncovered a phosphorylation switch (CK2/GSK3–MLX) that stabilizes ChREBP–MLX heterotetramers to control carbohydrate/lipid programs, offering a druggable nutrient-s

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlights paradigm-shifting mechanistic work, high-quality translational evidence, and clinically actionable genomic diagnostics. Key advances include identification of endogenous cyanide as a regulatory gasotransmitter affecting mitochondrial bioenergetics, convergent human-and-animal evidence that GLP-1 receptor agonists reduce alcohol intake (supporting rapid repurposing trials), and large-scale genetic screening establishing non-coding HK1 regulatory var

Weekly Endocrinology Research Analysis

This week in endocrinology saw advances spanning precision prescribing, adipose and mineral metabolism mechanisms, and novel diagnostic/prognostic markers. A Lancet real-world model offers a five-class decision tool to personalize glucose‑lowering therapy and improve 12‑month HbA1c. Translational studies highlighted LRP5 and BDH1 as actionable adipose and ketone‑epigenetic pathways influencing metabolic and cardiac outcomes, while clinical biomarker work (cFGF‑23, IA‑2A, anthropometric clusters)

Weekly Endocrinology Research Analysis

This week in endocrinology was defined by large-scale resource development, mechanistic epigenetics, and practice-informing clinical trials. A new adipose tissue multi-omics portal (Cell metabolism) promises to accelerate cross-cohort discovery and translational target validation. Mechanistic work in Cell Metabolism showed caloric restriction can reverse oocyte methylation changes that mediate intergenerational PCOS risk, while long-term randomized surgical data (SM-BOSS) clarify durability and

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlights three high-impact advances: mechanistic neuroendocrine work revealing a POMC→paraventricular thalamus μ‑opioid microcircuit that paradoxically drives sugar appetite in sated states; a multicenter proof-of-concept showing endoscopic ultrasound–guided radiofrequency ablation (EUS‑RFA) as a safe, adrenal-sparing option for left-sided aldosterone-producing adenomas; and preclinical discovery that macrophages protect sensory axons in diabetic peripheral

Weekly Endocrinology Research Analysis

This week highlighted mechanistic and translational advances across endocrine metabolism: (1) sensory neuron Piezo2 signaling was shown to restrain adipose thermogenic remodeling and systemic hypermetabolism, revealing a novel neurometabolic axis; (2) a dominant lysosomal (LIPA/LAL–MiT/TFE) lipolysis pathway was identified that mobilizes adipose energy during prolonged fasting, reframing lipolytic physiology; and (3) mitonuclear/ISR signaling was shown to de-differentiate metabolic tissues with

Weekly Endocrinology Research Analysis

This week featured papers that shift practice and mechanistic understanding across endocrinology: a data-driven IPD meta-analysis identified baseline CRP as a clear biomarker to guide adjunct corticosteroid use in hospitalized community-acquired pneumonia; discovery of a sleep‑inducible hypothalamic hormone (Raptin) defines a new sleep–metabolism endocrine axis and a potential anti‑obesity target; and an inpatient randomized trial showed CGM‑guided insulin titration markedly improves time‑in‑ran

Weekly Endocrinology Research Analysis

This week’s endocrinology literature emphasized translational advances spanning practice-changing clinical trials and mechanistic discoveries with therapeutic potential. A multicenter double-blind RCT shows dapagliflozin added to calorie restriction substantially increases 12‑month remission of type 2 diabetes. Mechanistic studies identify targetable liver and hepatic‑metabolic axes (a liver→brain vagal sensory pathway and a USP25→PPARα deubiquitination axis) that modulate steatosis and metaboli

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlighted several mechanistic discoveries redefining inter-organ endocrine control and translational advances that will influence clinical practice. Two Science papers revealed new endocrine/neuroimmune axes — muscle‑derived myostatin driving pituitary FSH synthesis and a fasting-activated catecholaminergic neuron → ILC2 → pancreas circuit controlling glucagon — shifting thinking about organ cross-talk. Large clinical trials and cohorts advanced therapeutic

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlights mechanistic and translational advances linking microbiome and redox biology to systemic endocrine disease, along with pragmatic clinical studies that refine therapeutics and monitoring. A mechanistic mycobiome–AhR axis was implicated in PCOS, while pentose phosphate pathway and PRDX1 redox regulation revealed new targets for cartilage and liver disease respectively. Large trials and meta-analyses clarified clinical practice: time-restricted eating

Weekly Endocrinology Research Analysis

This week’s endocrinology literature highlights mechanistic advances that directly affect diagnosis and potential therapies. A multi-modal reclassification of the INS R6C variant establishes it as a recessive cause of monogenic diabetes, altering genetic counseling and variant interpretation frameworks. Translational work links diet-driven exosomal miR-17-3p to idiopathic short stature and demonstrates a corrective exosome-based strategy in preclinical models. Immuno-mechanistic data identify ga